Dr. Catherine Devoe
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Columbia University College of Physicians and Surgeons (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 174
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Columbia University College of Physicians and Surgeons
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A150759 (first issued 2017; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
- Regents of the University of California (732 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 174
- Services billed
- 554
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 125 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 96 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 53 | 36 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 40 | 40 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 19 | 17 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 18 | 14 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 18 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 60 |
| Lisinopril Other prescribers in San Francisco, CA | 39 |
| Zerbaxa (ceftolozane/tazobactam) | 39 |
| Triumeq (abacavir/dolutegravir/lamivudi) | 35 |
| Doxycycline Hyclate Other prescribers in San Francisco, CA | 32 |
| Dovato (dolutegravir sodium/lamivudine) | 28 |
| Tivicay (dolutegravir sodium) | 24 |
| Gabapentin Other prescribers in San Francisco, CA | 23 |
| Atorvastatin Calcium Other prescribers in San Francisco, CA | 22 |
| Metoprolol Succinate Other prescribers in San Francisco, CA | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,236 in research payments for these studies, mostly to the institutions running them.
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.